



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	Ms_JCTI_20417
Title of the Manuscript:	Prognostic Value of KRAS Mutations in Patients with Colorectal Cancer: South Egypt Cancer Institute Experience
Type of the Article	Original Research Article

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
Thank you for the corrections, but it is necessary to edit the text, because there are some grammatical and stylistic errors (see first review). The manuscript was not corrected by a professional editor. If you use the title "Prognostic Value of <i>KRAS</i> Mutations in Codons 12 and 13 in South Egyptian Colorectal Cancer Patients", you should add "Acknowledgements" and include the South Egypt Cancer Institute and/or something/somebody else. It necessary to change "Results .3" to "3. Results:" It necessary to change "The age ranged from 34 to 68 years (The mean age: 50.8 years $\pm$ 11.0)." to "The age ranged from 34 to 68 years (the mean age: 50.8 years $\pm$ 11.0)." Table 1 It necessary to delete "%" for each result excepting the the title of column (No. of mutations (%) out of 25 cases). Table 1 It necessary to change "No. of mutations (%) Out of 25 cases" to "No. of mutations (%) out of 25 cases". Footnotes should be placed below the table with superscript lowercase letters(see Author's Instruction). Table 2-3 It necessary to delete "%" for each result excepting the the title of 2 columns. Figure 3-6 Each figure should have a caption. The caption should be concise and typed separately, not on the figure area (see Author's Instruction).(see first review) The captions have not deleted from figures area. Abbreviations have not revised (see first review): Non-standard abbreviations should be listed and full form of each abbreviation should be given in parentheses at first use in the text(see Author's Instruction): "2.3 Statistical method: Overall survival (OS) was defined as the interval from enrollment to the date of death	



SDI FINAL EVALUATION FORM 1.1

from any cause or last follow up.”;
The title of axis (Figure 3, 5) “% **Overall survival (OS)**”.

1. Introduction:
“... a phase III randomized trial of patients with stage III colon cancer demonstrated the prognostic value of *KRAS* mutation status (3-year **DFS**)...” (It was a first use, but there is not a full form).

2.3 Statistical method:
“**Disease free survival (DFS)** was defined as the interval from enrollment of patients to the date of relapse or death from any cause or last follow up.”
The title of axis (Figure 3, 5) “% **Disease free survival (DFS)**”.

“Furthermore, the CTRL reaction was used to display a normal **wild type (WT)** specific melting temperature as reference.”
“**WILD type (WT)** LOW reaction:”

“**Colorectal cancer (CRC)** is the fourth most common cancer in men and the third most common in women [1]. Approximately 40% of **colorectal cancers (CRCs)** harbor ...”;
“This study included 79 previously untreated **colorectal cancer (CRC)**”
“13 **C (Cystein)** LOW reaction: Sample must show a peak at about 56°C 12 **C (Cystein)** HIGH reaction:”

Guideline for Reporting *P* values:
P is always italicized and capitalized. Correct expression: (*P* = .05)(see Author's Instruction). (**see first review**). It was not capitalized and italicized: “...(83.1% vs 90.7%, p=0.04) ...”

It necessary to change the title of axis (Figure 4,6) “% Disease free survival (DFS)” to “DFS, %”

It necessary to change the title of axis (Figure 3, 5) “% Overall survival (OS)” to “OS, % ” .

It necessary to change “-ve” negative, “+ve” positive” to “The symbol “-ve” means negative value and the symbol “+ve” means positive value” or to another explication.

“*KRAS*” gene must be in italic type (**see first review**). It has not italicized in all places:
“Kras status” in the Figure 3-4.

“2.1.1 Surgery:
... the margins were examined histopathologically and subjected to *KRAS* mutation analysis.”
“PCR amplifications:
The assay was based on the PCR amplification of a fragment from exon/intron 1 of the human *KRAS* gene ...”

“2.2 *Tissue handling*
KRAS mutation detection”
“Samples displayed a clear peak in the HIGH reaction contained a mutated *KRAS* gene.”
“Figure 2: *KRAS* mutation detection assay for 3 cases of colorectal cancer “
“*KRAS* mutation detection assay for 3 cases of colorectal cancer revealed that each sample represented by 3 reactions...”
“... patterns of failure and *KRAS* mutation status, ...”
“... (25 out of 79) in *KRAS* gene.”
“Among 25 cases with *KRAS* mutated CRC, ...”
“Table 1: Distribution of the 25 mutations of *KRAS* gene”
Table 3 “*KRAS* mutation status”
“However, Bazan et al, showed an association between the *KRAS* mutation...”
“Wangefjord et al., reported similar survival for patients with *KRAS* wild-type and codon 12-mutated tumors, while patients with tumors harbouring a *KRAS* codon 13 mutation had



SDI FINAL EVALUATION FORM 1.1

a significantly reduced Cancer specific survival (HR = 1.94; 95% CI = 1.18–3.19) in unadjusted, but not in adjusted analysis [18].” Why was “Cancer” capitalized?
 “Imamura et al., observed that specific *KRAS* mutations ...”
 “Andreyev et al., reported that the presence of a somatic *KRAS* mutation”
 “... while *KRAS* codon 12 mutations were not significantly associated with reduced DFS or OS.”

You can use “gene name + gene” or “*gene name italicized*”:
 “Detection of mutations in the region codons 12 to 13 of the *KRAS* gene, in particular mutations 12D, 12C, 12V, 12A, 12R, 12S, 12T, 13D, 12D13D and 13C.”
 “Samples which contained significant amounts of mutated *KRAS* gene copies (>10-20%), ...”

There are some errors:
 “...South Egypt Cancer Institute from January 2011 to June **2013and** all patients were evaluated ...”
 “in particular mutations 12D, 12C, 12V, 12A, 12R, 12S, 12T, 13D, **12D13D** and 13C.”
 “proliferation and differentiation signals [**4,5**]. ”
 “...some studies reported no association with survival [**7,8**],...”
 “therapy in metastatic setting [**10,11**].”
 “**Histologically** proven CRC”
 “Capcitabine was given concurrent with radical radiotherapy by a dose 825 mg/ m² **twice daily**. “
 “South Egypt cancer **Institute**”

... etc.

Figure 5:
 Why was the word “Codon” capitalized?

2.2 *Tissue handling*
 It necessary to change “*KRAS* mutation detection” to “*KRAS* mutation detection.” .

“The DNA yield vary from 15- 150 ng/*ul*” Where is the point? Why was“*ul*” italicized?

Why was“2.2 *Tissue handling*” italicized? “2.1 Diagnosis and treatment.” was not italicized.

Why was different size of type used in the text of discussion?

“CRC cases between 2000 and 2002 and found that the median age was 53 years (Range 21-81 years)...” Why was “Range” capitalized?

“...the presence of lymph node metastasis and high SPF...”. What is “SPF”?

The abbreviations “ASRs”, “(ECOG)” and “(SECI)” was not used after the first mention. It is necessary to delete “(ASRs)”, “(ECOG)” and “(SECI)”:
 “age-standardized rates (ASRs)” in the discussion.
 “...South Egypt cancer Institute (SECI)” in the discussion.
 “...Eastern Cooperative Oncology Group (ECOG) system” in Patients and Methods.

It necessary to change “6.Consent:”, “7. Ethical Approval:”, “8. Competing interest:”, “9. References:” to “Consent:”, “Ethical Approval:”, “Competing interest:”, “References:”

It necessary to change “Abstract:”, “1. Introduction:”, “2. Patients and Methods:”, “3. Results:”, “5. Conclusion:” to “Abstract”, “1. Introduction”, “2. Patients and Methods”, “3. Results”, “5. Conclusion”.



SDI FINAL EVALUATION FORM 1.1

All references should follow the following style (**see first review**):

1. Hilly M, Adams ML, Nelson SC. A study of digit fusion in the mouse embryo. Clin Exp Allergy. 2002;32(4):489-98. (see Author's Instruction):
"1.Siegel R, Naishadham D and Jemal A: Cancer statistics.CA Cancer J Clin **Jan-Feb** 2012;62(1):10-29."
.... etc.

Please, correct other similar errors.

Reviewer Details:

Name:	Olga Berillo
Department, University & Country	Al-Farabi Kazakh National University, Almaty, Kazakhstan